Since the beginning of 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread all over the world, and a wide clinical spectrum of coronavirus disease-19 (COVID-19) has also been observed in solid organ transplant recipients, in whom immunosuppressive therapy and comorbidities affect the severity of the infection. We report a case of a 50-year-old woman who underwent liver transplantation for secondary sclerosing cholangitis.Despite the ongoing infection by SARS-CoV-2, the patient received the appropriate immunosuppressive treatment for graft rejection without progression to severe COVID-19. In addition, early beginning of anti-inflammatory, antifibrotic, antithrombotic therapy, and PE might have hampered the development of cytokine storm and endothelial damage despite prolonged high viral replication, thus preventing clinical progression.

Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection / M. Merli, C. Alteri, L. Colagrossi, G. Perricone, S. Chiappetta, G. Travi, D. Campisi, M.T. Pugliano, M. Vecchi, C. Orcese, S. Rossini, L. De Carlis, C. Vismara, L. Belli, C.F. Perno, M. Puoti. - In: TRANSPLANTATION. - ISSN 1534-6080. - 105:2(2021 Feb), pp. e22-e24. [10.1097/TP.0000000000003592]

Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection

C. Alteri
Secondo
;
2021

Abstract

Since the beginning of 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread all over the world, and a wide clinical spectrum of coronavirus disease-19 (COVID-19) has also been observed in solid organ transplant recipients, in whom immunosuppressive therapy and comorbidities affect the severity of the infection. We report a case of a 50-year-old woman who underwent liver transplantation for secondary sclerosing cholangitis.Despite the ongoing infection by SARS-CoV-2, the patient received the appropriate immunosuppressive treatment for graft rejection without progression to severe COVID-19. In addition, early beginning of anti-inflammatory, antifibrotic, antithrombotic therapy, and PE might have hampered the development of cytokine storm and endothelial damage despite prolonged high viral replication, thus preventing clinical progression.
COVID-19; Female; Graft Rejection; Humans; Middle Aged; Polydeoxyribonucleotides; Viral Load; Liver Transplantation; Plasma Exchange; SARS-CoV-2
Settore MED/07 - Microbiologia e Microbiologia Clinica
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
60.Transplantation_2021.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 375.48 kB
Formato Adobe PDF
375.48 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/823543
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact